A Phase I/II Study of Pembrolizumab and M032 (NSC 733972)
Status:
Not yet recruiting
Trial end date:
2024-12-20
Target enrollment:
Participant gender:
Summary
This Phase I (Cohort I and Cohort II) and Phase II trial is designed to confirm the safety
and tolerability of Pembrolizumab when given in conjunction with M032, an oHSV that
ex-presses IL-12 and perform the Phase II portion using a Recommended Phase 2 Dose (RP2D) of
M032 (provided by the Phase I) when given in conjunction with Pembrolizumab for recurrent
malignant glioma (glioblastoma multiforme, anaplastic astrocytoma, or glio-sarcoma).